CPO、能源金属、半导体板块跌幅居前。 09:30 算力概念股调整，特发信息接近跌停，长飞光纤、天孚通信、光库科技、长芯博创、罗博特科、 德科立等纷纷低开。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | | HSI | 恒生指数 | 26447.05 c | 66.03 | 0.25% | | HSTECH 恒生科技 | | 5117.24 c | 7.91 | 0.15% | 09:23 央行公开市场开展2690亿元7天期逆回购操作，操作利率1.40%。Wind数据显示，今日无逆回购到 期。 09:16 人民币兑美元中间价报6.9228，较前一交易日持平。 沪指低开0.43%，深成指跌0.89%，创业板指跌1.23%。科创综指跌1.06%。CPO、光纤、能源金属、半 导体板块跌幅居前，旅游及酒店、港口航运板块小幅走高。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | | 000001 上证指数 | | 4128.90 -17.73 -0.43% | | | | 3 ...

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) for its hemoadsorption device to treat endotoxic septic shock. Following recent interaction with the FDA, the Company now expects to submit its PMA around the end of April to mid-M ...

Group 1: IPO Activities - Hangzhou companies are accelerating their IPO processes, with two IPO applications submitted and nearly 20 financing events occurring between February 11 and February 24 [1] - Green Cloud Software Co., Ltd. submitted its prospectus to the Hong Kong Stock Exchange on February 20, aiming to become the first "smart travel stock" in Hong Kong [2] - BonaSia (Hangzhou) Pharmaceutical Technology Co., Ltd. also submitted its prospectus to the Hong Kong Stock Exchange on February 11, focusing on digital solutions for clinical research [3] Group 2: Financing Trends - The financing market in Hangzhou is thriving, with nearly 20 financing events reported, highlighting the strong interest in innovative companies [4] - Qianxun Intelligent, a company specializing in robotics, completed two rounds of financing totaling nearly 2 billion yuan, marking it as a significant player in the financing landscape [4] - Many of the recent financing events are concentrated in early-stage companies, with notable investments in firms like Lanrui Optoelectronics and Huamai Medical [4] Group 3: Robotics Sector Highlights - The robotics sector in Hangzhou has emerged as a major beneficiary of recent financing, with several companies securing significant funding [5] - Companies like Juwei Technology and Xihu Robotics have successfully raised funds to enhance their product development and industrialization efforts [5] - The focus on robotics and intelligent algorithms is driving innovation and investment in this sector, contributing to the overall growth of the industry [5]

证券代码：600216 证券简称：浙江医药 公告编号：2026-003 浙江医药股份有限公司与私募基金合作投资公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 投资标的名称：廊坊信慧银发经济股权投资基金合伙企业（有限合伙）（以下简称"合伙企业"、"标 的基金"）。 ● 出资金额：合伙企业的全部认缴出资额为8亿元，浙江医药股份有限公司（以下简称"公司"）作为有 限合伙人以自有资金认缴出资2.5亿元，占合伙企业认缴出资总额的31.25%。 根据公司《章程》等有关规定，本次交易未达到公司董事会及股东会审议标准，无需提交董事会或股东 会审议，后续合伙企业尚需履行工商变更登记、基金备案等程序。 ● 相关风险提示 合伙企业在后期运营过程中，所投资项目可能受到宏观经济、行业周期、投资标的运营管理等多种因素 影响，投资进展及项目完成情况存在一定的不确定性，存在无法实现预期收益乃至投资本金受损的风 险。 一、合作情况概述 （一）合作的基本概况 2026年2月24日，公司与普通合伙人中信医疗健康股权投资私募基金管理（北京） ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2025 financial results. Quanterix will issue a press release regarding its fourth quarter and full year 2025 financial results prior to the conference call on Monday, March 2, 2026. ...

Tech stocks continue to dominate the investing conversation on Wall Street – hardly a new development, but this month, the dialogue has turned slightly more bearish than what we’re used to. With the latest artificial intelligence (AI) models threatening to upend entire industries, investors are now chattering about the possibility of a “software Armageddon” that could wipe out legacy blue-chips. And up at the very top of the tech food chain, massive AI spending forecasts by the Magnificent 7 has revived ...

Core Viewpoint - Advanced Biomed Inc. announced a reverse stock split at a ratio of 1 for 20 shares, effective February 20, 2026, to comply with Nasdaq Listing Rule 5550(a)(2) [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split was approved by a majority of the voting power on January 12, 2026, with the board finalizing the ratio on January 30, 2026 [2]. - The objective of the reverse split is to enable the company to meet the minimum bid price requirement of $1.00 per share on Nasdaq [3]. - Following the reverse split, the total issued and outstanding common shares will decrease from 27,290,710 to approximately 1,364,536 shares [6]. Group 2: Shareholder Impact - Each 20 shares will convert into one share, maintaining the par value of US$0.001, and will not alter stockholders' percentage ownership, except for minor changes due to fractional shares [4]. - No fractional shares will be issued; stockholders will receive one full share instead of any fractional share resulting from the split [5]. Group 3: Company Overview - Advanced Biomed Inc. is a biotechnology company focused on innovative biomedical products for precision medicine and advanced diagnostics [1][7]. - The company operates through a subsidiary in Taiwan and has developed a proprietary microfluidic platform for advanced circulating tumor cell detection and analysis [8].

Core Insights - The automotive industry in Jiading is undergoing a significant transformation, with a focus on smart and connected vehicles, aiming to exceed a scale of 300 billion yuan by 2025 [2] - Jiading's integrated circuit industry is projected to achieve a total output of 105.8 billion yuan by 2025, reflecting a 3.8% year-on-year growth [3] - The biopharmaceutical sector is rapidly developing, with initiatives aimed at establishing Jiading as a leading hub for high-end medical devices and innovative therapies [8] Automotive Industry - Jiading's automotive sector is transitioning from testing and demonstration to large-scale commercial applications, with the Shanghai International Automobile City collaborating with 18 major car manufacturers to create a transparent supply chain management platform [2] - The government plans to accelerate the development of a world-class smart connected new energy vehicle innovation hub by 2026, with a focus on high-value and new energy models [2] - The evolution of vehicles into intelligent terminals is supported by advancements in high-performance automotive chips and solid-state battery production [2] Integrated Circuit Industry - Jiading is positioned as a key player in Shanghai's integrated circuit strategy, with a focus on domestic production capabilities and a complete industry chain [5] - The establishment of innovation centers and collaborative platforms is aimed at enhancing the local semiconductor manufacturing ecosystem [5] - The development of specialized companies, such as Liyang Chip, demonstrates the effectiveness of the regional industrial cluster strategy [3] Biopharmaceutical Industry - The biopharmaceutical sector is characterized by rapid growth, with significant projects like the establishment of high-end medical device clusters and innovative treatment centers [8] - Jiading aims to create a comprehensive ecosystem for precision medicine, integrating clinical research and application [8] - The collaboration with institutions like Ruijin Hospital and Fudan University is expected to foster advancements in biotechnologies and medical devices [8] Social and Cultural Development - Jiading's development strategy includes social initiatives such as the provision of affordable housing and community services, enhancing the quality of life for residents [10] - Cultural events like the Shanghai Auto Culture Festival are expected to boost tourism and local consumption [2][10] - The integration of industry and community development reflects Jiading's commitment to a balanced approach to urban growth [10]

在产业发展方面，该区域将承接南中轴地区和亦庄新城核心地区功能外溢，规划重点保障生物医药和商 业航天两大特色产业发展，助力国际科技创新中心功能建设。其中，生物医药产业以国际医药创新公园 为空间载体，商业航天产业以"北京火箭大街"项目为引擎。 本报讯（记者 陈雪柠）昨天，记者从市规划自然资源委获悉，《亦庄新城综合配套服务区YZ00—0401 —0405、0801—0805、0901—0905街区控制性详细规划（街区层面）（2020年—2035年）》获得批复。 《街区控规》明确，综合配套服务区定位为未来产业新引擎、生态宜居后花园，重点保障生物医药和商 业航天两大特色产业发展，助力亦庄新城打造"新质生产力典范区、国际一流高端产业综合新城"。 综合配套服务区位于亦庄新城西北部，西接南中轴及其延长线，东临亦庄新城核心地区，行政区划涉及 亦庄镇、旧宫镇和瀛海镇，包括15个街区，总用地面积约5761.97公顷。在生态景观方面，该区域将坚 持疏解与整治并举，推动城乡建设用地减量，提升绿色开敞空间占比，其中要以南海子公园为核心，打 造公园集群，完善文化休闲、户外体验、教育研学等配套设施，打造全龄友好休闲"后花园"。 ...

Group 1 - The core idea is to enhance the development capability of the Chengdu-Chongqing economic circle by establishing the Chengdu main axis economic corridor, the Cheng (Mian) Nan Da Wan economic belt, and the Minjiang-Changjiang upstream economic belt [1][2] - The government report emphasizes the importance of improving the comprehensive transportation system between Chengdu and Chongqing, and advancing the construction of the Chengdu-Chongqing high-speed rail and highway expansion projects [1][2] - The establishment of a regional technology innovation center in the Chengdu-Chongqing area aims to strengthen advanced manufacturing clusters in electronics and biomedicine [1][2] Group 2 - The discussion among representatives highlights the need to amplify Chengdu's radiating and driving role, which is seen as a crucial step in constructing a new pattern of regional coordinated development [2][3] - Collaboration between Chengdu and other cities, such as Mianyang and Nanchong, is essential for strengthening industrial cooperation and leveraging local resources [2][3] - The focus on infrastructure connectivity is underscored, with plans to enhance waterway transport and other major infrastructure projects to improve regional integration [3][4]